Share：
Share this content in WeChat
X
[Chinese][PDF]85993
• Review •
Progress of MRI in evaluating the efficacy of neoadjuvant therapy for rectal cancer
LI Jipin  MAO Lei  ZHOU Xueting  MA Wenli  XIE Zhuanhong  WANG Xiang 

Cite this article as: Li JP, Mao L, Zhou XT, et al. Progress of MRI in evaluating the efficacy of neoadjuvant therapy for rectal cancer[J]. Chin J Magn Reson Imaging, 2021, 12(4): 121-124. DOI:10.12015/issn.1674-8034.2021.04.031.


[Abstract] The widespread use of neoadjuvant chemoradiotherapy (nCRT) for rectal cancer has improved the prognosis of many patients, but some patients have not benefited. Magnetic resonance imaging (MRI) of rectum is a very effective imaging technique for diagnosing and comprehensively evaluating treatment of rectal cancer because of its high soft tissue resolution and better displaying of tumor invasion and changes of rectal wall. This article, from the aspect of different MRI technologies, MRI combined with laboratory examination, endoscopy and PET-CT, reviews the diagnostic value of MRI in predicting pathological response after neoadjuvant chemoradiotherapy for rectal cancer, aiming to provide a basis for clinical diagnosis and treatment.
[Keywords] rectal cancer；magnetic resonance imaging；neoadjuvant chemoradiotherapy；pathological response

LI Jipin1   MAO Lei1   ZHOU Xueting1   MA Wenli1   XIE Zhuanhong1   WANG Xiang2*  

1 The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China

2 Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou 730030, China

Wang X, E-mail: wangxiang@lzu.edu.cn

Conflicts of interest   None.

Received  2020-11-05
Accepted  2021-01-11
DOI: 10.12015/issn.1674-8034.2021.04.031
Cite this article as: Li JP, Mao L, Zhou XT, et al. Progress of MRI in evaluating the efficacy of neoadjuvant therapy for rectal cancer[J]. Chin J Magn Reson Imaging, 2021, 12(4): 121-124. DOI:10.12015/issn.1674-8034.2021.04.031.

1
Liu Z, Zhang XY, Shi YJ, et al. Radiomics analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Clin Cancer Res, 2017, 23(23): 7253-7262. DOI: 10.1158/1078-0432.CCR-17-1038.
2
van de Velde CJ, Boelens PG, Borras JM, et al. Eurecca colorectal: Multidisciplinary management: European consensus conference colon & rectum[J]. Eur J Cancer, 2014, 50(1): 1-34. DOI: 10.1016/j.ejca.2013.06.048.
3
Fujita S, Mizusawa J, Kanemitsu Y, et al. Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (Jcog0212): A multicenter, randomized controlled, noninferiority trial[J]. Ann Surg, 2017, 266(2): 201-207. DOI: 10.1097/SLA.0000000000002212.
4
Ryan JE, Warrier SK, Lynch AC, et al. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A systematic review[J]. Colorectal Dis, 2016, 18(3): 234-246. DOI: 10.1111/codi.13207.
5
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172. DOI: 10.1016/S0140-6736(13)62422-8.
6
Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data[J]. Lancet Oncol, 2010, 11(9): 835-844. DOI: 10.1016/S1470-2045(10)70172-8.
7
Sao Juliao GP, Habr-Gama A, Vailati BB, et al. New strategies in rectal cancer[J]. Surg Clin North Am, 2017, 97(3): 587-604. DOI: 10.1016/j.suc.2017.01.008.
8
Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the Oncore Project): A propensity-score matched cohort analysis[J]. Lancet Oncol, 2016, 17(2): 174-183. DOI: 10.1016/S1470-2045(15)00467-2.
9
Liu S, Zhong GX, Zhou WX, et al. Can endorectal ultrasound, MRI, and mucosa integrity accurately predict the complete response for mid-Low rectal cancer after preoperative chemoradiation? A prospective observational study from a single medical center[J]. Dis Colon Rectum, 2018, 61(8): 903-910. DOI: 10.1097/DCR.0000000000001135.
10
Beets-Tan RGH, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European society of gastrointestinal and abdominal radiology (ESGAR) consensus meeting[J]. Eur Radiol, 2018, 28(4): 1465-1475. DOI: 10.1007/s00330-017-5026-2.
11
KSAR study group for rectal cancer. Essential items for structured reporting of rectal cancer MRI: 2016 consensus recommendation from the Korean society of abdominal radiology[J]. Korean J Radiol, 2017, 18(1): 132-151. DOI: 10.3348/kjr.2017.18.1.132.
12
Jhaveri KS, Hosseini-Nik H. MRI of rectal cancer: An overview and update on recent advances[J]. AJR Am J Roentgenol, 2015, 205(1): W42-55. DOI: 10.2214/AJR.14.14201.
13
Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, et al. Pathologic complete response in rectal cancer: Can we detect it? lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer[J]. Dis Colon Rectum, 2016, 59(4): 255-263. DOI: 10.1097/DCR.0000000000000558.
14
Kim S, Han K, Seo N, et al. T2-weighted signal intensity-selected volumetry for prediction of pathological complete response after preoperative chemoradiotherapy in locally advanced rectal cancer[J]. Eur Radiol, 2018, 28(12): 5231-5240. DOI: 10.1007/s00330-018-5520-1.
15
Shihab OC, Taylor F, Salerno G, et al. MRI predictive factors for long-term outcomes of low rectal tumours[J]. Ann Surg Oncol, 2011, 18(12): 3278-3284. DOI: 10.1245/s10434-011-1776-2.
16
Jang JK, Choi SH, Park SH, et al. MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: A systematic review and meta-analysis for accuracy[J]. Eur Radiol, 2020, 30(4): 2312-2323. DOI: 10.1007/s00330-019-06565-2.
17
Bhoday J, Smith F, Siddiqui MR, et al. Magnetic resonance tumor regression grade and residual mucosal abnormality as predictors for pathological complete response in rectal cancer postneoadjuvant chemoradiotherapy[J]. Dis Colon Rectum, 2016, 59(10): 925-933. DOI: 10.1097/DCR.0000000000000667.
18
Barral M, Eveno C, Hoeffel C, et al. Diffusion-weighted magnetic resonance imaging in colorectal cancer[J]. J Visc Surg, 2016, 153(5): 361-369. DOI: 10.1016/j.jviscsurg.2016.08.004.
19
Chandramohan A, Siddiqi UM, Mittal R, et al. Diffusion weighted imaging improves diagnostic ability of MRI for determining complete response to neoadjuvant therapy in locally advanced rectal cancer[J]. Eur J Radiol Open, 2020, 7: 100223. DOI: 10.1016/j.ejro.2020.100223.
20
Lambregts DMJ, Delli Pizzi A, Lahaye MJ, et al. A pattern-based approach combining tumor morphology on MRI with distinct signal patterns on diffusion-weighted imaging to assess response of rectal tumors after chemoradiotherapy[J]. Dis Colon Rectum, 2018, 61(3): 328-337. DOI: 10.1097/DCR.0000000000000915.
21
Yang L, Qiu M, Xia C, et al. Value of high-resolution DWI in combination with texture analysis for the evaluation of tumor response after preoperative chemoradiotherapy for locally advanced rectal cancer[J]. AJR Am J Roentgenol, 2019 Mar 12, 1-8. DOI: 10.2214/AJR.18.20689. DOI: .
22
De Felice F, Magnante AL, Musio D, et al. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy[J]. Eur J Surg Oncol, 2017, 43(7): 1324-1329. DOI: 10.1016/j.ejso.2017.03.010.
23
Pham TT, Liney GP, Wong K, et al. Functional MRI for quantitative treatment response prediction in locally advanced rectal cancer[J]. Br J Radiol, 2017, 90(1072): 20151078. DOI: 10.1259/bjr.20151078.
24
Delli Pizzi A, Cianci R, Genovesi D, et al. Performance of diffusion-weighted magnetic resonance imaging at 3.0 T for early assessment of tumor response in locally advanced rectal cancer treated with preoperative chemoradiation therapy[J]. Abdom Radiol (NY), 2018, 43(9): 2221-2230. DOI: 10.1007/s00261-018-1457-8.
25
Jensen JH, Helpern JA, Ramani A, et al. Diffusional kurtosis imaging: The quantification of non-gaussian water diffusion by means of magnetic resonance imaging[J]. Magn Reson Med, 2005, 53(6): 1432-1440. DOI: 10.1002/mrm.20508.
26
Yu J, Xu Q, Song JC, et al. The value of diffusion kurtosis magnetic resonance imaging for assessing treatment response of neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Eur Radiol, 2017, 27(5): 1848-1857. DOI: 10.1007/s00330-016-4529-6.
27
Cheng XT, Cui YF, Yang XT. Value of diffusion kurtosis imaging in predicting and assessing response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Chin J Anat Clin, 2019, 24(6): 531-536. DOI: 10.3760/cma.j.issn.2095-7041.2019.06.003.
28
Hu F, Tang W, Sun Y, et al. The value of diffusion kurtosis imaging in assessing pathological complete response to neoadjuvant chemoradiation therapy in rectal cancer: A comparison with conventional diffusion- weighted imaging[J]. Oncotarget, 2017, 8(43): 75597-75606. DOI: 10.18632/oncotarget.17491.
29
Wang LL, Li SH, Huang G. Study on biological characteristics of rectal cancer based on magnetic resonance diffusion kurtosis imaging[J]. Chin J Magn Reson Imaging, 2020, 11(1): 35-39. DOI: 10.12015/issn.1674-8034.2020.01.008.
30
Dijkhoff RAP, Beets-Tan RGH, Lambregts DMJ, et al. Value of DCE-MRI for staging and response evaluation in rectal cancer: A systematic review[J]. Eur J Radiol, 2017, 95: 155-168. DOI: 10.1016/j.ejrad.2017.08.009.
31
Zhou ZP, Tang RJ, Tan XJ, et al. Correlation between dynamic contrast-enhanced MRI and tumor angiogenesis in rectal cancer[J]. J Med Imaging, 2017, 27(10): 1953-1957.
32
Petrillo A, Fusco R, Petrillo M, et al. DCE-MRI time-intensity curve visual inspection to assess pathological response after neoadjuvant therapy in locally advanced rectal cancer[J]. Jpn J Radiol, 2018, 36(10): 611-621. DOI: 10.1007/s11604-018-0760-1.
33
Gollub MJ, Blazic I, Felder S, et al. Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer[J]. Eur Radiol, 2019, 29(3): 1104-1113. DOI: 10.1007/s00330-018-5719-1.
34
Tong T, Sun YQ, Cai SJ, et al. Value of dynamic contrast-enhanced MRI in predicting response to neoadjuvant chemoradiation in locally advanced rectal cancer[J]. Chin J Radiol, 2015, 49(6): 414-418. DOI: 10.3760/cma.j.issn.1005-1201.2015.06.005.
35
Yi X, Pei Q, Zhang Y, et al. MRI-based radiomics predicts tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Front Oncol, 2019, 9: 552. DOI: 10.3389/fonc.2019.00552.
36
Aker M, Ganeshan B, Afaq A, et al. Magnetic resonance texture analysis in identifying complete pathological response to neoadjuvant treatment in locally advanced rectal cancer[J]. Dis Colon Rectum, 2019, 62(2): 163-170. DOI: 10.1097/DCR.0000000000001224.
37
Bulens P, Couwenberg A, Intven M, et al. Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics[J]. Radiother Oncol, 2020, 142: 246-252. DOI: 10.1016/j.radonc.2019.07.033.
38
Shu ZY, Fang SH, Ding ZX, et al. Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer[J]. Chin J of Gastroint Surg, 2018, 21(9): 1051-1058. DOI: 10.3760/cma.j.issn.1671-0274.2018.06.014.
39
Yoo GS, Park HC, Yu JI, et al. Carcinoembryonic antigen improves the performance of magnetic resonance imaging in the prediction of pathologic response after neoadjuvant chemoradiation for patients with rectal cancer[J]. Cancer Res Treat, 2020, 52(2): 446-454. DOI: 10.4143/crt.2019.261.
40
Reece M, Saluja H, Hollington P, et al. The use of circulating tumor DNA to monitor and predict response to treatment in colorectal cancer[J]. Front Genet, 2019, 10: 1118. DOI: 10.3389/fgene.2019.01118.
41
Ji XY. ct DNA in the diagnosis of colorectal cancer[D]. Guangzhou: South China University of Technology, 2017.
42
Dossa F, Chesney TR, Acuna SA, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2017, 2(7): 501-513. DOI: 10.1016/S2468-1253(17)30074-2.
43
Cho MS, Kim H, Han YD, et al. Endoscopy and magnetic resonance imaging-based prediction of ypT stage in patients with rectal cancer who received chemoradiotherapy: Results from a prospective study of 110 patients[J]. Medicine (Baltimore), 2019, 98(35): e16614. DOI: 10.1097/MD.0000000000016614.
44
Aiba T, Uehara K, Nihashi T, et al. MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer[J]. Ann Surg Oncol, 2014, 21(6): 1801-1808. DOI: 10.1245/s10434-014-3538-4.
45
Ippolito D, Fior D, Trattenero C, et al. Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer[J]. World J Radiol, 2015, 7(12): 509-520. DOI: 10.4329/wjr.v7.i12.509.

PREV Application progress of magnetic resonance imaging in diabetic kidney disease
NEXT
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn